Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassiony, Sarah, Harrison, Claire N, McLornan, Donal P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524184/
https://www.ncbi.nlm.nih.gov/pubmed/33061394
http://dx.doi.org/10.2147/TCRM.S258704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524184/
https://www.ncbi.nlm.nih.gov/pubmed/33061394
http://dx.doi.org/10.2147/TCRM.S258704

Ejemplares similares